arrow
A

Amy E. DeZern

Johns Hopkins University
H指数:57
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms

CALR突变骨髓增殖性肿瘤的结局异质性

2026-10-070
PRE
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

高风险骨髓增生异常综合征/新生物患者接受去甲基化药物+维奈克拉治疗后的结局分析——国际骨髓增生异常综合征(icMDS)VALIDATE数据库分析

2026-06-290
OAAI
American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia

美国血液学学会2026年严重获得性再生障碍性贫血的诊断和管理指南

2026-04-010
OAAI
Modeling the evolutionary dynamics of clonal hematopoiesis

模拟克隆性造血的进化动力学

2026-02-160
PRE
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53

Naji, N.S.; Pasca, S.; Chatzilygeroudi, T.; Toledano-Sanz, P.; Rimando, J.; An, Y.; Hemani, Y.; Perkins, B.; Zeng, X.; Talbot, C.; 等. C-C基序趋化因子受体样2促进具有红系分化和TP53突变髓系肿瘤的干扰素-γ信号反应。Haematologica, 2025. [Google Scholar] [CrossRef]

2026-02-013
OA
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

DDX41突变髓系肿瘤挑战现有的预后方案,并需要专门的危险评分系统:一项多中心、回顾性研究

Leukemia
IF13.4
2025-12-030
PRE
Long-term follow-up of the Baltimore experience with hematopoietic cell transplantation for severe aplastic anemia using post-transplant cyclophosphamide

采用移植后环磷酰胺治疗严重再生障碍性贫血的巴尔的摩经验长期随访研究

2025-11-050
PRE
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy
2025-11-011
OA
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

国际骨髓增生异常综合征/骨髓肿瘤工作组关于骨髓报告标准化的共识

2025-10-010
OA
Efficacy and safety of blinatumomab for CD19+acute leukemias in patients historically excluded from clinical trials due to comorbidities

Blinatumomab对由于合并症而被历史性地排除在临床试验之外的CD19+急性白血病患者中的有效性和安全性

2025-09-010
OAAI
A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE

比较治疗相关和原发性MDS的1590例与4738例患者预后变量和细胞遗传学异常的比较,包括MDS阶段治疗的影响

2025-09-010
PRE